RSS   Newsletter   Contact   Advertise with us
Post Online Media

Silence Therapeutics appoints Annalisa Jenkins to board

Silence TherapeuticsSilence Therapeutics, a novel RNA therapeutics company, announced the appointment of Annalisa Jenkins, CEO of Dimension Therapeutics as chair of Silence's board of directors.

A biopharma thought leader, Dr. Jenkins brings over 25 years of global industry experience to Silence's Board with a wealth of knowledge in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally.

Article continues below

READ MORE Silence Therapeutics appoints David Ellam as CFO

Prior to Dimension, Dr. Jenkins held multiple leadership positions, including executive vice president, head of Global Research and Development for Merck Serono.

She led Global Medical Affairs and Quality and was a member of Merck Serono's Pharmaceutical Executive Committee.

Previously, Dr. Jenkins had a nearly 15-year successful career at Bristol-Myers Squibb (BMS), attaining the role of senior vice president and head of Global Medical Affairs.

During her tenure at BMS, she played a key role in the development, approval, and/or commercialization of products in multiple therapeutic areas, including immuno-oncology, cardiology, immunology and infectious diseases.

Dr. Jenkins began her career as a medical officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander.

Dr. Jenkins graduated in medicine from St. Bartholomew's Hospital, London, and trained in cardiovascular medicine in the UK National Health Service.




What to read next



 LATEST MOVES FROM United Kingdom 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy